NuCana (NCNA) Competitors $0.03 0.00 (-1.83%) Closing price 04:00 PM EasternExtended Trading$0.03 0.00 (-5.90%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NCNA vs. EVFM, OGEN, NMTR, PTPI, ZVSA, SRNE, PBLA, BPTSY, ORGS, and HEPAShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Evofem Biosciences (EVFM), Oragenics (OGEN), 9 Meters Biopharma (NMTR), Petros Pharmaceuticals (PTPI), ZyVersa Therapeutics (ZVSA), Sorrento Therapeutics (SRNE), Panbela Therapeutics (PBLA), Biophytis (BPTSY), Orgenesis (ORGS), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Its Competitors Evofem Biosciences Oragenics 9 Meters Biopharma Petros Pharmaceuticals ZyVersa Therapeutics Sorrento Therapeutics Panbela Therapeutics Biophytis Orgenesis Hepion Pharmaceuticals NuCana (NASDAQ:NCNA) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation. Which has stronger valuation and earnings, NCNA or EVFM? Evofem Biosciences has higher revenue and earnings than NuCana. Evofem Biosciences is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuCanaN/AN/A-$24.28M-$7.020.00Evofem Biosciences$11.39M0.10$52.98M-$0.05-0.19 Do analysts rate NCNA or EVFM? NuCana currently has a consensus target price of $5,000.00, indicating a potential upside of 15,527,850.31%. Given NuCana's stronger consensus rating and higher probable upside, equities analysts plainly believe NuCana is more favorable than Evofem Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, NCNA or EVFM? NuCana has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.99, meaning that its share price is 199% less volatile than the S&P 500. Do insiders and institutionals believe in NCNA or EVFM? 44.0% of NuCana shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is NCNA or EVFM more profitable? NuCana has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets NuCanaN/A -319.85% -88.55% Evofem Biosciences -46.42%-91.97%-61.93% Does the media refer more to NCNA or EVFM? In the previous week, NuCana had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for NuCana and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of -0.50 beat NuCana's score of -1.00 indicating that Evofem Biosciences is being referred to more favorably in the news media. Company Overall Sentiment NuCana Negative Evofem Biosciences Negative SummaryNuCana beats Evofem Biosciences on 9 of the 15 factors compared between the two stocks. Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$196K$2.98B$5.45B$9.68BDividend YieldN/A2.46%3.99%4.14%P/E Ratio0.0017.9230.1125.01Price / SalesN/A178.92379.5578.79Price / CashN/A41.8335.9458.58Price / Book0.027.268.135.68Net Income-$24.28M-$54.43M$3.26B$265.68M7 Day PerformanceN/A-0.01%1.15%2.51%1 Month PerformanceN/A5.13%2.82%1.88%1 Year PerformanceN/A10.24%28.41%24.00% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana2.5903 of 5 stars$0.03-1.8%$5,000.00+15,527,850.3%-99.0%$196KN/A0.0030Negative NewsUpcoming EarningsGap UpEVFMEvofem Biosciences0.8945 of 5 stars$0.01+1.1%N/A-7.1%$1.09M$11.39M-0.01120Negative NewsOGENOragenics0.1359 of 5 stars$1.26+0.8%N/A-95.4%$1.04MN/A-0.185NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220PTPIPetros PharmaceuticalsN/A$0.03-1.9%N/A-99.7%$991K$5.11M-0.0120ZVSAZyVersa Therapeutics0.3625 of 5 stars$0.18-2.8%N/A-94.8%$878KN/A0.002Gap UpSRNESorrento Therapeutics0.8878 of 5 stars$0.00flatN/A-81.3%$827K$60.32M0.00800PBLAPanbela Therapeutics0.0925 of 5 stars$0.16-7.1%N/A-54.9%$767KN/A0.006Negative NewsBPTSYBiophytisN/A$1.81flatN/AN/A$634KN/A0.0030ORGSOrgenesis1.2093 of 5 stars$0.11-88.9%N/AN/A$533K$662K0.00150Gap DownHEPAHepion Pharmaceuticals0.475 of 5 stars$0.04-2.1%N/A-99.8%$480KN/A-0.0120Upcoming EarningsGap Down Related Companies and Tools Related Companies Evofem Biosciences Competitors Oragenics Competitors 9 Meters Biopharma Competitors Petros Pharmaceuticals Competitors ZyVersa Therapeutics Competitors Sorrento Therapeutics Competitors Panbela Therapeutics Competitors Biophytis Competitors Orgenesis Competitors Hepion Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NCNA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NCNA Stock Alerts